Hanyang University

A Breakthrough in Underarm Odor Control and Axillary Bromhidrosis Treatment SEOUL, South Korea, June 16, 2025 /PRNewswire/ -- CodeSteri Inc., a tech-driven startup based at the Hanyang University College of Medicine in Seoul, today announced the launch of PlaDeo, the world's first electronic deodorant device powered by bio-plasma. Designed to eliminate underarm odor safely and effectively, PlaDeo offers a revolutionary approach to managing axillary bromhidrosis—a medical condition characterized by chronic underarm odor—without the use of chemicals, pore-blocking agents, or aluminum salts. Continue Reading In 2020, PlaDeo—then branded Pragrant—was awarded the CES Innovation Award in the Health & Wellness category, recognizing its disruptive potential in personal care technology. Unlike conventional deodorants that mask odor using synthetic fragrances or suppress sweat glands, PlaDeo employs reactive oxygen species (ROS)—including hydroxyl radicals (OH⁻) and superoxide ions (O₂⁻)—to directly neutralize odor-causing bacteria and molecular residues on the skin. This plasma-powered mechanism ensures a non-toxic, non-residue, and skin-safe experience for daily users. Scientifically Validated Performance PlaDeo's efficacy has been scientifically proven. A peer-reviewed study published in Scientific Reports (2024), along with a clinical trial conducted at Hanyang University Hospital, demonstrated that 94% of participants experienced significant odor reduction after using the device regularly. These results validate PlaDeo as not only a hygiene product, but also a clinically relevant solution for those suffering from persistent body odor. The launch of PlaDeo comes at a time when global consumers are actively seeking chemical-free, science-supported alternatives for personal hygiene. With increasing awareness of the long-term risks posed by ingredients such as triclosan and aluminum compounds, PlaDeo addresses a growing demand for effective, health-conscious innovation in the deodorant market. Its compact, travel-friendly form factor also makes it ideal for use in gyms, offices, eldercare environments, and hospitals—anywhere discretion and hygiene intersect. Key Features: CES Award-Winning Plasma Technology: Kills bacteria and neutralizes odor at the source. Clinically Proven: Scientifically validated by peer-reviewed studies and human trials. Chemical-Free and Skin-Friendly: No residue, no irritation—just clean you. Portable and Easy to Use: Compact design for daily personal or medical use. PlaDeo is now available for pre-order on Indiegogo. For more details or to back the campaign, visit the official project page at: SOURCE Codesteri WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

4月4日，强生公司对外宣布，其TREMFYA®（guselkumab）的3b期APEX研究达到了主要终点（ACR20a），即与安慰剂相比，在成人活动性银屑病关节炎（PsA）患者中减少了体征和症状，同时也达到了其主要次要终点，即在24周时通过放射学进展评估减少了结构损伤的进展。TREMFYA®是首个也是唯一一个获准用于治疗PsA的全人源双效单克隆抗体，它可阻断IL-23，同时与CD64结合，CD64是产生IL-23的细胞上的受体。IL-23是由活化的单核细胞/巨噬细胞以及树突状细胞分泌的细胞因子，已知其为包括活动性银屑病关节炎在内的免疫介导疾病的驱动因素。在3b期APEX研究中，与接受安慰剂的患者相比，接受TREMFYA®治疗的患者在第24周时通过银屑病关节炎改良版van der Heijde-Sharp（vdH-S）评分（包括关节间隙变窄和侵蚀亚评分）评估的结构损伤进展也显著减少。数据与TREMFYA®已知的安全性特征一致，未发现新的安全性信号。“银屑病关节炎可能是一种渐进性和使人衰弱的疾病，如果不进行早期识别和治疗，患者可能会出现不可逆的关节损伤，严重影响其日常活动，”强生公司创新药物部门风湿病学疾病领域负责人Terence Rooney副总裁表示。“这些新的初步数据强调了尽早从源头上解决炎症和结构损伤的重要性。作为唯一一种显示出显著抑制结构损伤的IL-23治疗方法，TREMFYA®为医护人员提供了关键数据，使其患者不必在未来关节健康方面妥协。”APEX是一项3b期研究，具有长达三年的长期扩展数据，将进一步评估TREMFYA®对活动性PsA患者结构损伤抑制的持续疗效。APEX研究的结果正在准备中，将在即将召开的医学会议上展示。药事纵横投稿须知：稿费已上调，欢迎投稿

Amid doctors' strikes, the Ministry of Health and Welfare in South Korea has announced a new project that will harness artificial intelligence in the development of a clinical decision support system for emergency departments. It is investing 22.8 billion won ($16.7 million) over the next five years in the project, which aims to meet the following objectives: Establish an ER database Develop technology for optimising the treatment process in the ER Develop an AI model for experiencing the ER Develop a CDSS for predicting conditions such as cardiac arrest, cardiovascular diseases, and sepsis The project has involved five major hospitals, including Samsung Medical Center, Seoul Asan Medical Center, Korea University Medical Center, Gangnam Severance Hospital and Hanyang University Hospital. Korea's National Emergency Medical Center will also join the project to provide data and support AI demonstration, while the MOHW's Korea Health Industry Promotion Agency will also lend support through task management and evaluation and consultation. WHY IT MATTERS In a statement, the MOHW said it initiated the project to explore national-level solutions to pressing hospital issues, particularly the lack of emergency medical resources and poor emergency medical capabilities of health facilities outside metropolitan cities. The government has also noted the demand among members of the Korean Society of Emergency Medicine and the Korean Society Of Artificial Intelligence in Medicine for emergency room AI that supports the early detection of patient deterioration and reduction of patient wait times. THE LARGER TREND Since February, around 10,000 junior doctors across the nation have been on strike, filing mass resignations and going on mass walkouts to protest the government's plan to increase admission in medical schools – a measure thought to raise healthcare staffing to meet the growing healthcare demand in one of Asia's fast ageing societies. Their collective action has led to strains on emergency departments, with many forced to cut hours and cancel life-saving procedures. Since then, the government has tapped into military forces and retired doctors to keep the public health system running.